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In the management of advanced non-small cell lung cancer 
it is now routine clinical practice to screen diagnostic 
specimens for activating mutations in epidermal growth 
factor receptor (EGFR) and KRAS and translocations 
involving ALK and ROS. When detected, these mutations 
directly inform clinical decision-making. In particular, 
patients with one of the common EGFR mutations, exon 
19 deletion or L858R, often respond extremely well to 
EGFR tyrosine kinases inhibitors (TKIs). However, almost 
inevitably patients will relapse and the most common 
mechanism of resistance is a secondary mutation in EGFR 
that alters the affinity of the binding pocket to ATP—the 
T790M mutation (1). 
This raises a number of interesting and clinically 
important questions. First, is the T790M mutation 
present in TKI-naïve biopsies or does it emerge during 
therapy? Second, what is the best way to detect the T790M 
mutation? Third, how should this information be used to 
guide clinical decision-making? 
Watanabe and colleagues in a recent publication 
in Clinical Cancer Research have made a significant 
contribution to the field (2). They demonstrate the potential 
to use droplet digital polymerase chain reaction (ddPCR) as 
an ultrasensitive tool for the detection of rare variants in a 
large cohort of patients undergoing surgical resection, and 
they show that approximately 80% of TKI-naïve patients 
have detectable T790M in mainly early stage disease.
Watanabe and colleagues chose to use a digital PCR 
assay. ddPCR is a relatively recent refinement of digital 
PCR; a protocol which has been around for over 20 years 
but has been relatively under-utilized (3). However, recent 
advances in platform development, notably the development 
of microdroplet protocols have led to a marked increase in its 
popularity (4,5). Digital PCR is itself a very simple concept 
(Figure 1). It involves diluting DNA into aliquots, which can 
be chambers in microfluidic devices or microdroplets (6). 
The aim is usually to dilute DNA so that each droplet has 
on average less than a single copy of the target DNA locus. 
Then the droplets are tested for the presence or absence of 
the target DNA. This binary outcome—positive or negative 
is what gives the technique the name “digital”. For point 
mutations differently labeled probes are used in a single 
reaction so that each microdroplet is tested for both the 
mutant and wild type species. 
Digital PCR, although having a less broad dynamic range, 
has certain advantages over standard quantitative PCR 
protocols in a number of clinically relevant scenarios (4). It 
can be used to measure the absolute number of copies of an 
individual DNA species in any given sample and it performs 
extremely well in the detection and quantification of rare 
variants (6,7). It is accurate and precise and the data produced 
is straightforward to interpret.
The authors used the RainDance platform, in which DNA 
from each sample is diluted into over 1 million picoliter-
sized drops also containing PCR master mix buffer, primers 
and probes labeled with different fluorophores—one that 
will recognize wild type EGFR; the other that recognizes the 
mutated sequence (EGFR, 2369C>T). The microdroplets 
are channeled past a laser excitation/detection reader 
apparatus equivalent to a flow cytometer. Each microdroplet 
will fluoresce differently dependent on whether or not they 
contain the wild type or mutated PCR amplicon.
A clear objective in this study was to devise an assay 
capable of detecting rare variant mutations that may be 
present at a mutant allele frequency (MAF) of much less 
than 1%. The authors were therefore painstaking in their 
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approach to establishing the sensitivity of the assay and 
the lower limit of valid detection of the T790M mutation. 
The lower limit of detection [what the authors termed the 
limit of blank (LOB)] is a measure of how wild type DNA 
performs in an assay and it defines the level above which an 
assay can be deemed positive. These attributes (sensitivity/
LOB) will vary with the platform used and the primers/
probe sets and need to be established and validated for all 
rare variant assays.
Through a series of control experiments using a variety 
of assumed wild type template DNAs, including cell lines 
that had been fixed and paraffin-embedded, the authors 
determined that ten or more positive droplets equated 
to a positive result. They went on to show, using spike-
in experiments, that the measured concentration of the 
mutation matched the expected concentration down to a 
MAF of 0.01%; and further showed that they were able 
to detect the mutant allele down to a MAF of 0.001%. 
Importantly, a subgroup of assays performed on patient 
biopsy DNA, was reproduced by a different operator on a 
different day and delivered almost identical results.
As regards the critical potential issue of FFPE-mediated 
bias (8), this was addressed by sampling normal tissue 
adjacent to tumor in 16 patients—8 with EGFR mutated 
disease and eight with EGFR—wild type disease and 
demonstrating no excess of T790M mutations in either 
group.
In summary, this represents a very sensitive, reproducible 
and robust assay for the detection of EGFR T790M in 
patient-derived specimens. 
To put the detection sensitivity in context, the published 
results of a competing technology—targeted next 
generation sequencing—range from 0.4–2% in the analysis 
of cfDNA (9,10), although reports on small numbers of 
patients indicate that may be improved (11). The commonly 
used MiSeq platform was used as a comparator in this study 
with an estimated threshold of detection of 1.4%. 
Watanabe et al. went on to apply their validated protocol 
to the largest series of patients reported to date. Of the total 
of 373 patients, 89.2% had stage I or II disease, consistent 
with this being a surgical series. All patients had a mutation 
in EGFR with 94.9% being the commonly reported 
mutations—L858R or exon 19 deletion. Using the ddPCR 
assay a surprising 79.9% of patients were positive for the 
T790M mutation at baseline. In the vast majority of these 
individuals, and 75.3% of all patients, the T790M bearing 
cells represented a rare subclone with a MAF in the interval 
0.01–0.1%. 
It has been known for some time that T790M is present 
pre-treatment in a proportion of TKI-naïve EGFR mutant 
lung cancer. As assay sensitivity has increased, then so too 
has the reported prevalence of T790M—with the overall 
detection rate ranging from less than 10% using Sanger 
sequencing to 78.9% using colony PCR in a small cohort 
(12,13). The concern that very sensitive assays may yield 
false positives has been addressed in this study by the careful 
assay validation discussed above. Indeed one reasonable 
hypothesis may be that if a more sensitive protocol were 
developed or limitless tumor-derived DNA available, that 
an even higher proportion of tumors may be positive for 
Figure 1 Simple schematic of digital PCR. Sample DNA is 
diluted, to on average less than a haploid genome per microdroplet 
prior to the PCR. Each microdroplet contains the reagents 
required for the PCR reaction and the mutant and wild type 
probes which are labelled with different fluorophores. The PCR 
reaction is performed in the standard way and each droplet 
then tested using laser excitation for the presence or absence of 
the target DNA locus. In this case the rare variant T790M is 
represented in red and is present in only one microdroplet, while 
the wild type allele is present in the majority of microdroplets. 
A simple (and software automated) mathematical transformation 
is performed to estimate the mutant allele frequency (MAF) 
of  T790M. EGFR,  epidermal  growth factor  receptor. 
Figure 1. Simple schematic of digital PCR. Sample DNA is diluted, to on average 
less than a haploid genome per microdroplet prior to the polymerase chain 
reaction (PCR). Each microdroplet contains the reagents required for the PCR 
reaction and the mutant and wild type probes which are labelled with dierent 
uorophores. The PCR reaction is performed in the standard way and each 
droplet then tested using laser excitation for the presence or absence of the 
target DNA locus. In this case the rare variant T790M is represented in red and is 
present in only one microdroplet, while the wild type allele is present in the 
majority of microdroplets. A simple (and software automated) mathematical 
transformation is performed to estimate the mutant allele frequency of T790M. 
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T790M. This hypothesis is consistent with the observation 
that T790M was detectable in all EGFR-mutated specimens 
(but not controls) in which >150 ng of genomic DNA was 
analyzed. 
On the face of it this data suggests that in most cases, 
even in relatively early stage EGFR-mutant disease, that the 
resistance conferring T790M mutation is already present at 
the point of diagnosis. This is somewhat controversial for 
two reasons: first, the concerns raised that the detection of 
T790M rare variants in formalin-fixed paraffin-embedded 
specimens is biased by artifactual C>T transitions (8); 
and second, recent in vitro experiments suggest only a 
proportion of T790M-mediated resistance is present prior 
to treatment (14,15). These carefully performed studies 
identify a second group of “late” TKI-resistance clones. 
The authors suggest a model whereby T790M negative cells 
tolerate the TKI for a period (persister cells) before a clone 
with T790M or another resistance-conferring mutation 
emerges. 
There are many publications detailing the common and 
more infrequent mechanisms of resistance to TKIs in EGFR-
mutant lung cancer. These have usually been identified 
via rebiopsy of progressive disease and generally in the 
advanced disease setting rather than in early disease (1). The 
proportion of TKI-resistance generally ascribed to T790M 
mutation is near to 50%, which at first glance is at odds with 
the 80% prevalence reported in this study. However, multiple 
mechanisms of resistance can coexist at both the cellular and 
subclonal levels, and the presence of multiple subclones may 
be missed by the standard clinical practice of performing a 
single rebiopsy procedure on disease progression (1). It is 
standard practice to rebiopsy EGFR-mutant disease when 
there is progression on a TKI as establishing the mechanism 
of resistance often necessitates histological assessment (small 
cell transformation) or a FISH assay (MET amplification). It 
will be important in future studies to correlate results from 
rebiopsy specimens with cfDNA analyses (16). For example, 
it is a formal possibility that in the clinic T790M is actually 
much more common at relapse post-TKI than reported, 
but that in many individuals a separate dominant subclone 
outcompetes the minor T790M subclone.
So what will be the clinical utility of detection of “ultra” 
rare variants? It is difficult with current knowledge to 
integrate the detection of a subclone at 0.01% into clinical 
decision-making, particularly in resected disease. It is worth 
speculating that patients with markedly different T790M 
mutational loads (such as >10% vs. 0.01%) may have 
different outcomes, particularly in the advanced setting in 
which a selective pressure will be exerted by TKIs. 
The 3rd generation TKIs has potent in vitro activity against 
the activating mutations—L858R and exon 19 deletion, and 
against double mutants with either of these mutations plus 
T790M. These drugs now have proven clinical efficacy in 
T790M positive disease, albeit in early phase trials in the 
advanced setting. Should they be used as first-line therapies 
in advanced EGFR-mutant disease in which rare T790M 
events can be defined? 
The jury is firmly out on this suggestion. There are 
competing rationales. We know that initial responses to 1st 
and 2nd line TKIs are often impressive and that the most 
common resistance mechanism (T790M) is therapeutically 
tractable. We now also know that tertiary mutations and 
resistance mechanisms emerge in response to the 3rd 
generation TKIs, and these may not yet be therapeutically 
tractable (16,17). If such mutations were to emerge earlier 
as a result of upfront 3rd generation TKIs then overall 
outcomes may be poorer. However, the calculation may be 
different for those patients with a relatively high T790M 
MAF pretreatment. Further, the distinction between pre-
existing T790M mutations and the “persister cell” model 
could have profound implications for the choreography of 
treatment of EGFR-mutated lung cancer (14,15).
A separate question is whether decisions on adjuvant 
therapy could be informed by the detection of T790M in a 
surgical resection specimen. The role for adjuvant TKIs in 
EGFR mutated disease is not yet established (18).
There is therefore much scope for further research 
in this field that would be facilitated by a very sensitive, 
validated and robust assay for T790M status.
Finally, the authors reported associations between 
T790M mutation and various subgroups. Perhaps 
unsurprisingly the larger tumors and those with TP53 
mutations were more likely to have a T790M mutation. 
More intriguing was the association between PIK3CA 
mutation and T790M mutation, albeit in small numbers. 
This study is an important one because it sets the current 
benchmark in terms of the combination of EGFR T790M 
assay sensitivity and cohort size. It cements microdroplet 
digital PCR as a rational choice for robust, reproducible, 
easily interpreted assays. As with many good translational 
studies it raises as many questions as it addresses. First is it 
reproducible by other groups and in other cohorts? Is the 
community reassured that these ultrasensitive techniques 
are not delivering false positive results? Will this assay 
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be translatable to cfDNA and urine? Will stratification 
not only by the presence or absence of an activating 
mutation but also by T790M mutational load be clinically 
informative? Critically, when should 3rd generation TKIs 
be given to patients with detectable T790M? There are not 
always binary “digital”—answers to these questions.
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